Spinal delta opioid receptor subtype activity of 6-monoacetylmorphine in Swiss webster mice

Jodie J. Rady, Daniel Baemmert, A. E. Takemori, Philip S Portoghese, James M. Fujimoto

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Heroin and 6-monoacetylmorphine (6MAM) given intracerebroventricularly in Swiss Webster mice, act on supraspinal delta (δ) opioid receptors to produce antinociception in the tail flick test. More specifically, this action of heroin involves δ1 and 6MAM involves δ2 opioid receptors. Even though 6MAM given intrathecally (IT) in Swiss Webster mice also activates δ receptors to produce antinociception, the subtype of δ receptor in the spinal cord is not known. The present study addressed this question. First, in order to confirm the subtype selectivity of the δ opioid receptor antagonists in the spinal cord, 7-benzylidenenaltrexone (BNTX, a selective δ1 receptor antagonist) and naltriben (a selective δ2 receptor antagonist) were administered IT against the prototypic δ1 and δ2 peptide agonists [D-Pen2,5]enkephalin (DPDPE) and [D-Ser2,Leu5]enkephalin-Thr (DSLET), respectively. DPDPE-induced antinociception was inhibited by BNTX, but not naltriben. The opposite selectivity occurred for DSLET; naltriben, but not BNTX, administered IT inhibited IT DSLET-induced antinociception. Therefore, the antagonists differentiated between spinal δ1 and δ2 opioid receptor subtype agonist actions. This differentiation was further demonstrated by administration of the antagonists IT against the antinociceptive action of β-endorphin given intracerebroventricularly. The antinociceptive action of β-endorphin is due to spinal release of met-enkephalin which results in spinal δ2 receptor activation. This antinociception was reduced by IT naltriben, but not BNTX, administration. The antagonists were then administered against IT 6MAM-induced antinociception. Neither BNTX nor naltriben given alone, each at twice the usual dose, altered IT 6MAM-induced antinociception. When the antagonists were administered together, each at the usual dose, the antinociceptive action of 6MAM was inhibited. Thus, even though a differentiation between spinal δ1 and δ2 opioid receptor activity can be obtained with naltriben and BNTX, blockade of the individual δ receptor subtypes does not appear to alter IT 6MAM antinociception. Therefore, these results suggest that 6MAM, given IT, is acting on a δ opioid receptor but this receptor in the spinal cord appears to be different from the δ2 receptor on which 6MAM acts in the brain.

Original languageEnglish (US)
Pages (from-to)243-249
Number of pages7
JournalPharmacology Biochemistry and Behavior
Volume56
Issue number2
DOIs
StatePublished - Feb 1 1997

Fingerprint

delta Opioid Receptor
Enkephalins
Opioid Receptors
D-Penicillamine (2,5)-Enkephalin
Endorphins
Spinal Cord
Heroin
6-O-monoacetylmorphine
Methionine Enkephalin
Narcotic Antagonists
naltrindole benzofuran
Tail
Brain
Chemical activation
Peptides

Keywords

  • 6-monoacetylmorphine
  • 7-benzylidenena ltrexone
  • DPDPE
  • DSLET
  • antinociception
  • naltriben
  • spinal delta opioid receptor subtype

Cite this

Spinal delta opioid receptor subtype activity of 6-monoacetylmorphine in Swiss webster mice. / Rady, Jodie J.; Baemmert, Daniel; Takemori, A. E.; Portoghese, Philip S; Fujimoto, James M.

In: Pharmacology Biochemistry and Behavior, Vol. 56, No. 2, 01.02.1997, p. 243-249.

Research output: Contribution to journalArticle

Rady, Jodie J. ; Baemmert, Daniel ; Takemori, A. E. ; Portoghese, Philip S ; Fujimoto, James M. / Spinal delta opioid receptor subtype activity of 6-monoacetylmorphine in Swiss webster mice. In: Pharmacology Biochemistry and Behavior. 1997 ; Vol. 56, No. 2. pp. 243-249.
@article{dbdc32036abd42cb9a3bd0c35c958722,
title = "Spinal delta opioid receptor subtype activity of 6-monoacetylmorphine in Swiss webster mice",
abstract = "Heroin and 6-monoacetylmorphine (6MAM) given intracerebroventricularly in Swiss Webster mice, act on supraspinal delta (δ) opioid receptors to produce antinociception in the tail flick test. More specifically, this action of heroin involves δ1 and 6MAM involves δ2 opioid receptors. Even though 6MAM given intrathecally (IT) in Swiss Webster mice also activates δ receptors to produce antinociception, the subtype of δ receptor in the spinal cord is not known. The present study addressed this question. First, in order to confirm the subtype selectivity of the δ opioid receptor antagonists in the spinal cord, 7-benzylidenenaltrexone (BNTX, a selective δ1 receptor antagonist) and naltriben (a selective δ2 receptor antagonist) were administered IT against the prototypic δ1 and δ2 peptide agonists [D-Pen2,5]enkephalin (DPDPE) and [D-Ser2,Leu5]enkephalin-Thr (DSLET), respectively. DPDPE-induced antinociception was inhibited by BNTX, but not naltriben. The opposite selectivity occurred for DSLET; naltriben, but not BNTX, administered IT inhibited IT DSLET-induced antinociception. Therefore, the antagonists differentiated between spinal δ1 and δ2 opioid receptor subtype agonist actions. This differentiation was further demonstrated by administration of the antagonists IT against the antinociceptive action of β-endorphin given intracerebroventricularly. The antinociceptive action of β-endorphin is due to spinal release of met-enkephalin which results in spinal δ2 receptor activation. This antinociception was reduced by IT naltriben, but not BNTX, administration. The antagonists were then administered against IT 6MAM-induced antinociception. Neither BNTX nor naltriben given alone, each at twice the usual dose, altered IT 6MAM-induced antinociception. When the antagonists were administered together, each at the usual dose, the antinociceptive action of 6MAM was inhibited. Thus, even though a differentiation between spinal δ1 and δ2 opioid receptor activity can be obtained with naltriben and BNTX, blockade of the individual δ receptor subtypes does not appear to alter IT 6MAM antinociception. Therefore, these results suggest that 6MAM, given IT, is acting on a δ opioid receptor but this receptor in the spinal cord appears to be different from the δ2 receptor on which 6MAM acts in the brain.",
keywords = "6-monoacetylmorphine, 7-benzylidenena ltrexone, DPDPE, DSLET, antinociception, naltriben, spinal delta opioid receptor subtype",
author = "Rady, {Jodie J.} and Daniel Baemmert and Takemori, {A. E.} and Portoghese, {Philip S} and Fujimoto, {James M.}",
year = "1997",
month = "2",
day = "1",
doi = "10.1016/S0091-3057(96)00219-5",
language = "English (US)",
volume = "56",
pages = "243--249",
journal = "Pharmacology Biochemistry and Behavior",
issn = "0091-3057",
publisher = "Elsevier Inc.",
number = "2",

}

TY - JOUR

T1 - Spinal delta opioid receptor subtype activity of 6-monoacetylmorphine in Swiss webster mice

AU - Rady, Jodie J.

AU - Baemmert, Daniel

AU - Takemori, A. E.

AU - Portoghese, Philip S

AU - Fujimoto, James M.

PY - 1997/2/1

Y1 - 1997/2/1

N2 - Heroin and 6-monoacetylmorphine (6MAM) given intracerebroventricularly in Swiss Webster mice, act on supraspinal delta (δ) opioid receptors to produce antinociception in the tail flick test. More specifically, this action of heroin involves δ1 and 6MAM involves δ2 opioid receptors. Even though 6MAM given intrathecally (IT) in Swiss Webster mice also activates δ receptors to produce antinociception, the subtype of δ receptor in the spinal cord is not known. The present study addressed this question. First, in order to confirm the subtype selectivity of the δ opioid receptor antagonists in the spinal cord, 7-benzylidenenaltrexone (BNTX, a selective δ1 receptor antagonist) and naltriben (a selective δ2 receptor antagonist) were administered IT against the prototypic δ1 and δ2 peptide agonists [D-Pen2,5]enkephalin (DPDPE) and [D-Ser2,Leu5]enkephalin-Thr (DSLET), respectively. DPDPE-induced antinociception was inhibited by BNTX, but not naltriben. The opposite selectivity occurred for DSLET; naltriben, but not BNTX, administered IT inhibited IT DSLET-induced antinociception. Therefore, the antagonists differentiated between spinal δ1 and δ2 opioid receptor subtype agonist actions. This differentiation was further demonstrated by administration of the antagonists IT against the antinociceptive action of β-endorphin given intracerebroventricularly. The antinociceptive action of β-endorphin is due to spinal release of met-enkephalin which results in spinal δ2 receptor activation. This antinociception was reduced by IT naltriben, but not BNTX, administration. The antagonists were then administered against IT 6MAM-induced antinociception. Neither BNTX nor naltriben given alone, each at twice the usual dose, altered IT 6MAM-induced antinociception. When the antagonists were administered together, each at the usual dose, the antinociceptive action of 6MAM was inhibited. Thus, even though a differentiation between spinal δ1 and δ2 opioid receptor activity can be obtained with naltriben and BNTX, blockade of the individual δ receptor subtypes does not appear to alter IT 6MAM antinociception. Therefore, these results suggest that 6MAM, given IT, is acting on a δ opioid receptor but this receptor in the spinal cord appears to be different from the δ2 receptor on which 6MAM acts in the brain.

AB - Heroin and 6-monoacetylmorphine (6MAM) given intracerebroventricularly in Swiss Webster mice, act on supraspinal delta (δ) opioid receptors to produce antinociception in the tail flick test. More specifically, this action of heroin involves δ1 and 6MAM involves δ2 opioid receptors. Even though 6MAM given intrathecally (IT) in Swiss Webster mice also activates δ receptors to produce antinociception, the subtype of δ receptor in the spinal cord is not known. The present study addressed this question. First, in order to confirm the subtype selectivity of the δ opioid receptor antagonists in the spinal cord, 7-benzylidenenaltrexone (BNTX, a selective δ1 receptor antagonist) and naltriben (a selective δ2 receptor antagonist) were administered IT against the prototypic δ1 and δ2 peptide agonists [D-Pen2,5]enkephalin (DPDPE) and [D-Ser2,Leu5]enkephalin-Thr (DSLET), respectively. DPDPE-induced antinociception was inhibited by BNTX, but not naltriben. The opposite selectivity occurred for DSLET; naltriben, but not BNTX, administered IT inhibited IT DSLET-induced antinociception. Therefore, the antagonists differentiated between spinal δ1 and δ2 opioid receptor subtype agonist actions. This differentiation was further demonstrated by administration of the antagonists IT against the antinociceptive action of β-endorphin given intracerebroventricularly. The antinociceptive action of β-endorphin is due to spinal release of met-enkephalin which results in spinal δ2 receptor activation. This antinociception was reduced by IT naltriben, but not BNTX, administration. The antagonists were then administered against IT 6MAM-induced antinociception. Neither BNTX nor naltriben given alone, each at twice the usual dose, altered IT 6MAM-induced antinociception. When the antagonists were administered together, each at the usual dose, the antinociceptive action of 6MAM was inhibited. Thus, even though a differentiation between spinal δ1 and δ2 opioid receptor activity can be obtained with naltriben and BNTX, blockade of the individual δ receptor subtypes does not appear to alter IT 6MAM antinociception. Therefore, these results suggest that 6MAM, given IT, is acting on a δ opioid receptor but this receptor in the spinal cord appears to be different from the δ2 receptor on which 6MAM acts in the brain.

KW - 6-monoacetylmorphine

KW - 7-benzylidenena ltrexone

KW - DPDPE

KW - DSLET

KW - antinociception

KW - naltriben

KW - spinal delta opioid receptor subtype

UR - http://www.scopus.com/inward/record.url?scp=0031043999&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031043999&partnerID=8YFLogxK

U2 - 10.1016/S0091-3057(96)00219-5

DO - 10.1016/S0091-3057(96)00219-5

M3 - Article

VL - 56

SP - 243

EP - 249

JO - Pharmacology Biochemistry and Behavior

JF - Pharmacology Biochemistry and Behavior

SN - 0091-3057

IS - 2

ER -